How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AGIOS PHARMACEUTICALS via AGIOS PHARMACEUTICALS
2026 · third_quarter · Q3
Medicaid Reform
Sickle Cell Policy Biotech Innovation
Biotech Innovation
Source: Senate LDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGIOS PHARMACEUTICALS via AGIOS PHARMACEUTICALS
2026 · second_quarter · Q2
Biotech Innovation
Medicaid Reform
Sickle Cell Policy Biotech Innovation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGIOS PHARMACEUTICALS via AGIOS PHARMACEUTICALS
2026 · first_quarter · Q1
Medicaid Reform
Sickle Cell Policy Biotech Innovation
Biotech Innovation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGIOS PHARMACEUTICALS via AGIOS PHARMACEUTICALS
2025 · fourth_quarter · Q4
Sickle Cell policy Biotech innovation
Biotech Innovation
Medicaid Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGIOS PHARMACEUTICALS via AGIOS PHARMACEUTICALS
2025 · third_quarter · Q3
Sickle Cell policy Biotech innovation
Biotech Innovation
Medicaid Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGIOS PHARMACEUTICALS via AGIOS PHARMACEUTICALS
2025 · second_quarter · 2A
Sickle Cell policy Biotech innovation
Medicaid reform
Biotech innovation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AGIOS PHARMACEUTICALS via AGIOS PHARMACEUTICALS
2025 · second_quarter · RR
Pharmacy, Medicare/Medicaid, Health Issues
Pharmacy, Medicare/Medicaid, Health Issues
Pharmacy, Medicare/Medicaid, Health Issues